Abstract
One of the most clinically important objectives of therapy for atrial fibrillation is the prevention of stroke/thromboembolism. The risk of ischemic stroke in patients with atrial fibrillation may be related to multifactorial pathogenesis. The only therapy for atrial fibrillation with the effect of reducing mortality is anticoagulation with warfarin, not antiarrhythmic therapy. However, the management of atrial fibrillation includes a lot of modulating factors and should be carefully carried out on a case-by-case basis.
